Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

Prieto-Campo, Ángela; Zapata-Cachafeiro, Maruxa; Portela-Romero, Manuel; Piñeiro-Lamas, María; Figueiras, Adolfo; Salgado-Barreira, Ángel

doi:10.1016/j.rec.2023.12.004

Revista Española de Cardiología (English Edition)

2024

DOI: 10.1016/j.rec.2023.12.004

|View full text |Cite

Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

Ángela Prieto-Campo,

Maruxa Zapata-Cachafeiro,

Manuel Portela-Romero

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Harnessing immunity: Immunomodulatory therapies in COVID-19

Velikova,

Valkov,

Aleksandrova

et al. 2024

World J Virol

View full text Add to dashboard Cite

An overly exuberant immune response, characterized by a cytokine storm and uncontrolled inflammation, has been identified as a significant driver of severe coronavirus disease 2019 (COVID-19) cases. Consequently, deciphering the intricacies of immune dysregulation in COVID-19 is imperative to identify specific targets for intervention and modulation. With these delicate dynamics in mind, immunomodulatory therapies have emerged as a promising avenue for mitigating the challenges posed by COVID-19. Precision in manipulating immune pathways presents an opportunity to alter the host response, optimizing antiviral defenses while curbing deleterious inflammation. This review article comprehensively analyzes immunomodulatory interventions in managing COVID-19. We explore diverse approaches to mitigating the hyperactive immune response and its impact, from corticosteroids and non-steroidal drugs to targeted biologics, including anti-viral drugs, cytokine inhibitors, JAK inhibitors, convalescent plasma, monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2, cell-based therapies (i.e., CAR T, etc. ). By summarizing the current evidence, we aim to provide a clear roadmap for clinicians and researchers navigating the complex landscape of immunomodulation in COVID-19 treatment.

show abstract

Harnessing immunity: Immunomodulatory therapies in COVID-19

Velikova,

Valkov,

Aleksandrova

et al. 2024

World J Virol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

Cited by 1 publication

References 26 publications

Harnessing immunity: Immunomodulatory therapies in COVID-19

Harnessing immunity: Immunomodulatory therapies in COVID-19

Contact Info

Product

Resources

About